Patents
US patents through Dec 31, 2025 · PatentsView, from the USPTO’s Open Data Portal · read Oct 27, 2026
19 patents granted to the 2 names below, as the owner printed on each patent when it was granted. A later sale, a lapse or an expiry is not read, so this is what was granted to Celularity Inc.’s names, not what it holds today.
Patents granted
19
19 utility, 1976 to Dec 31, 2025
Granted in 2025
none
Against none in 2024 and 1 in 2023
Applications published
66
3 of them in 2025
Names they are printed under
2
its own name
By yearGrantedApplications published
'17'18'19'20'21'22'23'24'25
Each pair is one calendar year. Applications are published about eighteen months after filing, so the newest years read low.
What they are aboutgrants since 2021
Pharmaceuticals4
Biotechnology1
The main technology area of each patent, in the World Intellectual Property Organization’s 35 fields.
Under which name2 counted
Celularity Inc. its own name
US, as the owner printed on each patent
65 publishedCelularity Inc. its own name
named as the applicant on its applications, in US
1 published
Newest grantseach row opens the USPTO’s own copy
| Granted | Patent | Title | Field | Owner as printed |
|---|
| Jul 11, 2023 | 11,696,930 | Use of placental stem cells in treatment of acute kidney injury | Pharmaceuticals | Celularity Inc. |
| Nov 29, 2022 | 11,512,282 | Enhanced placental stem cells and uses thereof | Biotechnology | Celularity Inc. |
| Nov 23, 2021 | 11,180,731 | Methods of treating acute myeloid leukemia and multiple myeloma using natural killer cells | Pharmaceuticals | Celularity Inc. |
| Nov 16, 2021 | 11,173,182 | Placenta-derived adherent cell exosomes and uses thereof | Pharmaceuticals | Celularity Inc. |
| Aug 17, 2021 | 11,090,339 | Treatment of pain using placental stem cells | Pharmaceuticals | Celularity Inc. |
| Mar 17, 2020 | 10,590,381 | Composition for collecting and preserving placental stem cells and methods of using the composition | Biotechnology | Celularity Inc. |
| Feb 18, 2020 | 10,564,087 | Methods for quantifying particulates in cell culture | Measurement | Celularity Inc. |
| Feb 4, 2020 | 10,548,926 | Methods for collecting and using placenta cord blood stem cells | Pharmaceuticals | Celularity Inc. |
| Dec 3, 2019 | 10,494,607 | CD34+,CD45−placental stem cell-enriched cell populations | Biotechnology | Celularity Inc. |
| Aug 20, 2019 | 10,383,897 | Placental stem cell populations | Pharmaceuticals | Celularity Inc. |
Newest applications publishedan application is a clue, never a plan
| Published | Application | Title | Field | Owner as printed |
|---|
| Sep 25, 2025 | 2025/0295776 | CLEAVAGE RESISTANT CD16 CONSTRUCTS AND USES THEREOF | Biotechnology | Celularity Inc. |
| Sep 4, 2025 | 2025/0276063 | PLACENTA-DERVIED NK CELLS AS A SENOL YTIC FOR THERAPEUTIC AND OTHER USES | Medical technology | Celularity Inc. |
| Mar 20, 2025 | 2025/0092363 | PLACENTA-DERIVED ALLOGENEIC CAR-T CELLS AND USES THEREOF | Medical technology | Celularity Inc. |
| Jul 25, 2024 | 2024/0245830 | MULTI-LAYER AMNIOTIC TISSUE GRAFTS AND USES THEREOF | Medical technology | Celularity Inc. |
| Nov 9, 2023 | 2023/0355759 | POPULATIONS OF NATURAL KILLER CELLS COMPRISING A CLEAVAGE RESISTANT CD16 | Medical technology | Celularity Inc. |
| Oct 5, 2023 | 2023/0310319 | CULTIVATION OF PLACENTA TO ISOLATE EXOSOMES | Pharmaceuticals | Celularity Inc. |
| Sep 28, 2023 | 2023/0302058 | TREATMENT OF LYMPHEDEMA AND RELATED CONDITIONS USING PLACENTAL ADHERENT CELLS | Pharmaceuticals | Celularity Inc. |
| Jul 6, 2023 | 2023/0210909 | PLACENTA-DERIVED ADHERENT (PDA) STEM CELL FOR THE TREATMENT OF ADULTS WITH SARS-COV-2 RELATED ACUTE RESPIRATORY FAILURE AND ARDS (COVID-19) | Pharmaceuticals | Celularity Inc. |
| Jun 15, 2023 | 2023/0181649 | EXOSOMES FOR DISEASE TREATMENT | Pharmaceuticals | Celularity Inc. |
| May 11, 2023 | 2023/0142803 | NATURAL KILLER CELLS AND ILC3 CELLS AND USES THEREOF | Pharmaceuticals | Celularity Inc. |
What it applied for, 2024 to 2025: Medical technology 3 · Biotechnology 1.
A patent is counted where the owner printed on it when it was granted carries the company’s own name, a former name, the name of a subsidiary its annual report lists, or its own name with a patent-holding phrase (Technology Licensing, Intellectual Property and the like), once the legal form, case and punctuation are set aside, and prints a country that name counts in. PatentsView’s data are published under the Creative Commons Attribution 4.0 licence. Source: PatentsView's granted patents and pre-grant publications, disambiguated, from the USPTO's Open Data Portal, through Dec 31, 2025, read Oct 27, 2026.